Search

EP4144736A1 - Azabenzimidazoles AMPA Receptor Modulators, Janssen, Apr 15, 2026

The EPO published patent application EP4144736A1 titled 'Azabenzimidazoles and Their Use as AMPA Receptor Modulators' on April 15, 2026, covering novel heterocyclic compounds as AMPA receptor modulators for neurological and pain conditions. The application was filed by Janssen Pharmaceutica NV with 13 named inventors. The patent designates 37 EPO contracting states.

CHMP Meeting Agenda Annex Lists 22 Products Under Review

EMA's CHMP published an agenda annex for the March 23-26, 2026 meeting, listing 22 pharmaceutical products across multiple procedure types: 3 annual reassessments (Lojuxta, Raxone, Defitelio), 7 periodic safety update reports (CARVYKTI, Fycompa, Tecvayli, Qdenga, RINVOQ, Dengue Tetravalent Vaccine, Kapruvia, Voxzogo, ALTUVOCT), 5 renewals (Ezmekly, Lytgobi, Rozlytrek, Duvyzat, Aucatzyl, Fingolimod Mylan, Cometriq), and several variation type IB submissions. Rapporteurs, co-rapporteurs, and PRAC rapporteurs are assigned to each procedure.